Introduction {#s1}
============

Ras-associated binding protein 23 (RAB23) belongs to the RAB family of small GTPases, which function during several steps in cell vesicle trafficking ([@bib11]). RAB23 has 35--40% sequence homology with other RABs, it localizes to the plasma membrane and is proposed to regulate cargo internalization and relocation in the cell ([@bib11]; [@bib33]; [@bib38]; [@bib45]). RAB23 is unusual amongst RABs as it is involved in embryogenesis, for instance in heart and limb patterning, neural tube closure and skeletal development ([@bib10]; [@bib8]; [@bib13]; [@bib16]; [@bib19]). RAB23 negatively regulates Hh signaling during mouse neural tube development ([@bib10]), and it controls nodal signaling independently of Hh signaling during vertebrate left-right patterning ([@bib13]). RAB23 is involved in trafficking D1-type dopaminergic receptors ([@bib33]) and kinesin-2 motor protein Kif-17 ([@bib38]) to the primary cilium. However, direct ciliary function of RAB23 is unclear as cilium length and function are reported normal in *Rab23^-/-^* mice ([@bib11]; [@bib13]).

Multiple mutations in *RAB23* have been reported in patients with the autosomal recessive Carpenter syndrome; the majority of mutations result in nonsense-mediated decay while others include missense and in-frame deletions ([@bib24]). Carpenter syndrome (CS, MIM \#201000) or Acrocephalopolysyndactyly type II is a multi-organ developmental disorder with polysyndactyly, congenital heart defects, mental retardation, obesity and craniosynostosis as central features ([@bib4]; [@bib23]).

Craniosynostosis is the premature fusion of one or more craniofacial sutures that results in major disruption of face and skull growth. Mesenchymal cells in the center of the suture must be kept in an undifferentiated state to maintain suture patency, while progenitor cells at the osteogenic fronts proliferate and differentiate to facilitate bone growth. Suture biogenesis is dependent on the correct patterning of the skeletal elements, as well as the regulation of the mesenchymal stem cell niche, osteogenic condensation formation, osteoprogenitor proliferation and differentiation ([@bib55]; [@bib63]). These developmental processes are regulated to permit coordinated craniofacial growth, without the fusion of the neighboring bones and consequent cessation of growth.

Mutations in *FGFR*s are a major cause of syndromic craniosynostosis, with many of the mutations conferring a gain of function ([@bib17]; [@bib71]). FGFRs isoforms show a distinct FGF ligand binding affinity and biological functions ([@bib46]). However, studies have shown that in an Apert syndrome (*FGFR2* mutation) mouse model isoform FGFR2c loses ligand specificity, and is able to bind with cognate FGF10 ([@bib21]; [@bib22]; [@bib25]; [@bib73]). Interestingly, genetic knockdown of *Fgf10* in this mouse model could rescue the premature fusion ([@bib18]). FGF signaling pathway members have not been linked to RAB23-mediated trafficking. However, study suggests that RAB23 resides in the plasma membrane and proposed to be involved in endocytosis ([@bib11]). In this context, RAB23 might have a direct role in growth factor receptor recycling and turnover, and therefore regulate the availability of the FGF receptors at the cell surface ([@bib32]; [@bib74]).

Similar to Carpenter syndrome, several craniosynostosis syndromes caused by mutations in *FGFRs* are characterized by patients exhibiting syndactyly and occasionally polysyndactyly ([@bib15]; [@bib41]). Also, mutations in several hedgehog (Hh) pathway members cause polydactyly ([@bib40]; [@bib64]). Notably, Greig cephalopolysyndactyly syndrome (MIM **\#** 175700) is caused by haploinsufficiency of the Hh signaling negative regulator, *GLI3* ([@bib68]). In addition to the polysyndactyly, some patients with Greig cephalopolysyndactyly syndrome exhibit craniosynostosis, and the mouse model for Greig cephalopolysyndactyly syndrome (*Gli3^Xt-J/Xt-J^*) shows complete phenotypic penetrance for both craniosynostosis and polydactyly ([@bib20]; [@bib54]). Also, a recurrent mosaic mutation in the hedgehog receptor *Smoothened* (*SMO*) causes craniosynostosis and polysyndactyly ([@bib62]). These overlapping skeletal phenotypes caused by mutations in *FGFR*s, Hh regulators and *RAB23* are suggestive of common etiological mechanisms. FGF and Hh signaling have well-defined roles during intramembranous osteogenesis. FGF signaling regulates many stages including mesenchymal condensation formation, osteoprogenitor proliferation and differentiation and activation of the osteogenic transcription factor RUNX2 ([@bib7]; [@bib28]; [@bib46]; [@bib72]). IHH positively regulates osteoprogenitor recruitment to the osteogenic front and GLI transcription factors regulate stem cell maintenance and osteoprogenitor proliferation ([@bib37]; [@bib54]; [@bib66]; [@bib75]). Interestingly, RAB23 regulates GLI1 in a Su(Fu)-dependent manner ([@bib5]) and GLI1-positive cells have been identified in the suture as the main source of mesenchymal stem cells that plays crucial role in suture patency ([@bib75]).

The aim of this study was to determine the role of RAB23 during intramembranous bone development. Previously, it has not been possible to study skeletal development in RAB23 deficient mice due to their early lethality. Here, we generated RAB23 deficient (*Rab23^-/-^*) mice that survived until embryonic day (E) 18.5, and this allowed us to investigate how RAB23 regulates bone formation. Similar to Carpenter syndrome patients, RAB23 deficient mice exhibited polysyndactyly and multiple craniosynostoses. We show that disruption of *Rab23* leads to an upregulation of *Pitx2*, *Fgf10* and *Fgfr1b* expression, decreased p38 and enhanced pERK1/2-RUNX2 signaling along with elevated osteoprogenitor proliferation. In addition, *Hh* signaling was amplified with increased expression of GLI1. During in vitro culture, inhibition of elevated pERK1/2 normalized osteoprogenitor proliferation, corrected the aberrant GLI1 and RUNX2 expressions, and rescued the lambdoid suture fusion. Our results suggest a novel role for RAB23 as an upstream regulator of both FGF10-pERK1/2 and Hh-GLI1, and the additional regulation of GLI1 by pERK1/2, to coordinate the initiation of osteogenesis.

Results {#s2}
=======

*Rab23^-/-^* mice exhibit craniosynostosis in multiple sutures {#s2-1}
--------------------------------------------------------------

*Rab23 open brain 2 (opb2)* homozygous mutant mice did not produce RAB23 protein in primary cells, analyzed by western blot ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and will therefore be referred to as *Rab23^-/-^* mice. *Rab23^-/-^* C3 Heb/FeJ mice, generated through an ENU screen, survive until E12.5 rendering full analysis of organogenesis impossible ([@bib8]; [@bib27]). To obviate the gestation lethality before skeletal development, we backcrossed *Rab23^-/-^* C3 Heb/FeJ mice onto the C57Bl/6 strain. After six generations, the survival of the *Rab23^-/-^* homozygote embryos were prolonged to E18.5, and this allowed us to study skeletal development of these mice.

*Rab23^-/-^* mice at embryonic day E18.5 exhibited craniosynostosis in the coronal, parietal-temporal, fronto-nasal and in the lambdoid sutures when compared to their wild type (Wt) littermates ([Figure 1A--E](#fig1){ref-type="fig"}). The prevalence of premature suture fusion in *Rab23^-/-^* mice represented as percentage and only parieto-temporal sutures showed bi-lateral suture fusion (100%) in all the samples ([Figure 1F](#fig1){ref-type="fig"}). Along with craniosynostosis, *Rab23^-/-^* mice showed skeletal patterning defects in the forelimbs and hindlimbs. *Rab23^-/-^* mice showed pre-axial polydactyly (seven digits) of the forelimb and preaxial polysyndactyly (seven digits) of the hindlimbs ([Figure 1G](#fig1){ref-type="fig"}). Polydactyly and craniosynostosis were observed (100%) in all *Rab23^-/-^* samples examined.

![Deficiency of RAB23 causes premature fusion of multiple sutures and polysyndactyly.\
(**A--E**) Analysis of Wt and *Rab23^-/-^* skulls by µ-CT (**A--C**) and alizarin red, alcian blue staining (**D--E**) at E18.5. *Rab23^-/-^* skulls show fusion in the parieto-temporal suture (B-a, black arrow), coronal suture (B-a, green arrow and B-b, µ-CT slice, green arrow), frontonasal suture (C-a, arrow) and lambdoid suture (E-a, arrow). Wt sutures were open at this embryonic stage (**A--a, A--b**) (*n* = 10 for each age and genotype). fb: frontal bone, pb: parietal bone. Scale bar: 1 mm. (**F**) The prevalence of suture fusion in *Rab23^-/-^* mouse at E18.5 shown in percentage. Only parieto-temporal suture showed bi-lateral suture fusion in all the samples. (*n* = 10 for sagittal and interfrontal suture, n = 40 for lambdoid suture and n = 20 for other sutures). (**G**) Skeletal Analysis of the limbs in *Rab23^-/-^* mouse show pre-axial polydactyly of the fore limb (FL, 1a, 2a) and pre axial polysyndactyly of the hind limb (HL, 1a, 2a) at E18.5 (n = 10 for each age and genotype. Scale bar: 1.5 mm. (**H--K**) E18.5 mouse calvaria indicating fb: frontal bone, pb: parietal bone, ipb: interparietal bone and ls: lambdoid suture (**H**). Analysis of Wt and *Rab23^-/-^* calvaria by µ-CT at E18.5 shows *Rab23^-/-^* lambdoid sutures form bony protrusions from parietal bones project towards the interparietal bones (J, arrow), or ectopic bony islands in the mid-sutural mesenchyme (K, arrow) (n = 6 for each age and genotype). Scale bar: 500 µm. (**L**) Measurements of the lambdoid suture shows *Rab23^-/-^* lambdoid sutures are narrower as compare to the Wt samples at E18.5 (n = 6 for each age and genotype). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a p*-value \< *0.05 (\*). (**M**) In vitro calvaria culture system. This system was used to culture Wt and *Rab23^-/-^* calvaria containing patent lambdoid sutures at E17.5 and E18.5. (**N, O**) Represents E18.5 Wt and patent lambdoid suture containing *Rab23^-/-^* calvaria culture in vitro for 3 days in presence of alizarin red. *Rab23^-/-^* lambdoid suture shows fusion at day 3 (N, alizarin red bone staining, O, µ-CT images), whereas Wt controls remain open (n = 10 for each genotype). Scale bar: 500 µm. (**P**) *Rab23* expression in the whole calvarial tissue at E16.5 is shown by digoxigenin labeled whole mount in situ hybridization (**P--a**) and shown at E15.5 sutural tissue sections by RNAscope (**P--b**). Co-expression of RAB23 (green) and osteoblast marker RUNX2 (red) in the calvarial sutural section at E17.5 is shown by immunohistochemical staining (**P--c**), nuclear staining (blue). RAB23 protein expression in the sutures at E15.5 is shown by western blotting (**P--d**). fb: frontal bone, pb: parietal bone, ipb: interparietal bone, fs: frontal suture, ss: sagittal suture, ls: lambdoid suture. Scale bar: 500 µm (**a**), 100 µm (**b, c**).](elife-55829-fig1){#fig1}

At E18.5, 5% of *Rab23^-/-^* lambdoid sutures exhibited unilateral suture fusion ([Figure 1F](#fig1){ref-type="fig"}). Compared to Wt samples ([Figure 1I](#fig1){ref-type="fig"}), unfused *Rab23^-/-^* lambdoid sutures showed abnormal bony protrusions from parietal bones toward interparietal bone ([Figure 1J](#fig1){ref-type="fig"}) or ectopic bones in the lambdoid suture ([Figure 1K](#fig1){ref-type="fig"}). At this stage, *Rab23^-/-^* lambdoid sutures were narrower than Wt lambdoid sutures ([Figure 1L](#fig1){ref-type="fig"}). As 95% of *Rab23^-/-^* lambdoid sutures were consistently patent at E18.5 they were chosen as a model to study the role of RAB23 in osteogenesis. *Rab23^-/-^* mice die neonatally, therefore, analysis of *Rab23^-/-^* lambdoid suture beyond the E18.5 stage was assessed by in vitro calvarial explant culture ([@bib52]; [Figure 1M](#fig1){ref-type="fig"}). Wt and patent *Rab23^-/-^* lambdoid sutures harvested for culture at E18.5, *Rab23^-/-^* lambdoid sutures fused predictably after 3 days of culture ([Figure 1N,O](#fig1){ref-type="fig"}).

*Rab23* expression in calvaria and sutures {#s2-2}
------------------------------------------

*Rab23* mRNA expression was analyzed in whole calvaria and tissue sections by in situ hybridization and protein expression by immunohistochemical staining and western blotting. *Rab23* was expressed in suture mesenchyme with the strongest signal in interfrontal, sagittal and coronal sutures and parietal bone side of the lambdoid suture ([Figure 1P--a](#fig1){ref-type="fig"}). Analysis of tissue sections revealed *Rab23* expression in the osteogenic fronts of the calvarial sutures and throughout the sutural mesenchyme ([Figure 1P--b](#fig1){ref-type="fig"}). RAB23 was expressed in the lambdoid sutural osteogenic fronts and in the underlying cartilage. Co-expression with RUNX2 confirmed the cells in the osteogenic front to be osteoprogenitor or osteoblast ([Figure 1P--c](#fig1){ref-type="fig"}). The *Rab23* expression pattern was consistent with the phenotype of synostosed calvarial sutures observed in the *Rab23^-/-^* mice ([Figure 1B,C and E](#fig1){ref-type="fig"}). Western blotting of proteins extracted from E15.5 Wt calvarial frontal, sagittal and lambdoid sutures along with their osteogenic fronts confirmed the presence of RAB23 protein in the suture ([Figure 1P--d](#fig1){ref-type="fig"}).

*Rab23^-/-^* mice exhibit elevated levels of *Fgf10* and *Pitx2* in the calvaria and suture {#s2-3}
-------------------------------------------------------------------------------------------

To investigate differentially expressed genes between Wt and *Rab23^-/-^* calvaria and to find candidate genes responsible for the craniosynostosis in the RAB23-deficient mice, we performed a microarray-based gene expression analysis of whole Wt and *Rab23^-/-^* calvaria samples excluding the skin and underlying brain at E15.5 ([Figure 2A](#fig2){ref-type="fig"}). Our analysis revealed 223 significantly differentially expressed genes between the Wt and *Rab23^-/-^* calvaria (t-test, p\<0.05) ([Figure 2B](#fig2){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}, MIAME-compliant data has been deposited in GEO database as source data, GEO accession GSE140884). Among these genes, 115 genes were upregulated ([Figure 2B](#fig2){ref-type="fig"}, red) and 108 genes were downregulated ([Figure 2B](#fig2){ref-type="fig"}, green). *Fgf10* was found to be overexpressed in the microarray in *Rab23^-/-^* calvaria ([Figure 2C](#fig2){ref-type="fig"}). *Fgf10* was selected as a candidate for further analysis as it has previously been shown to be expressed early in calvarial development and has been implicated in craniosynostosis pathogenesis ([@bib18]; [@bib65]). *Fgf10* expression was elevated in whole calvarial mesenchyme, lambdoid sutural mesenchymal tissue and in calvaria derived (CD) mesenchymal cells at E15.5 as assessed by RT-qPCR ([Figure 2D](#fig2){ref-type="fig"}). Our microarray analysis also showed that the transcription factor *Pitx2* was elevated in *Rab23^-/-^* calvaria ([Figure 2C](#fig2){ref-type="fig"}). *Pitx2* is a well-documented upstream regulator of *Fgf10* and may act in a reciprocal regulatory loop with FGF10 during early organogenesis ([@bib1]). We found that *Pitx2* was overexpressed both in the *Rab23^-/-^* calvaria and in *Rab23^-/-^* lambdoid sutures ([Figure 2E](#fig2){ref-type="fig"}). *Pitx2* overexpression was further observed in *Rab23^-/-^* calvaria by whole-mount in situ hybridization in and surrounding the interparietal bone ([Figure 2F](#fig2){ref-type="fig"}).

![Gene expression analysis in Wt and *Rab23^-/-^* lambdoid suture.\
(**A**) Wt and *Rab23^-/-^* calvaria at E15.5 (dotted ring, excluding skin) processed for Illumina based microarray (n = 3 for each age and genotype). (**B**) Analysis of mRNA based microarray data by Chipster, a bioinformatics tool, reveals that 223 genes are differentially expressed (*t*-test, p\<0.05, 115 genes are upregulated, red and 108 genes are downregulated, green) in *Rab23^-/-^* calvaria, represented by volcano plot (n = 3 for each age and genotype). Fold change of genes is calculated by arithmetic mean in linear scale and shown in the volcano plot. Fold change \>1 (up-regulated gene), fold change \< 1 (down-regulated gene). The gene list is provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. (**C**) Represents individual searches of genes based on their contribution of suture fusion reveals *Fgf10* as a candidate gene and *Pitx2* as another developmentally important gene that can regulate *Fgf10* expression. Both genes are upregulated in *Rab23^-/-^* calvaria. (**D, E**) RT-qPCR analysis of *Fgf10* (**D**) and *Pitx2* (**E**) mRNA extracted from E15.5 Wt and *Rab23^-/-^* calvaria (excluding skin), cultured calvaria derived primary cells (CDC) and from lambdoid sutural tissue reveals that *Fgf10* and *Pitx2* are overexpressed in *Rab23^-/-^* samples (n = 3 calvaria and eight lambdoid sutures for each genotype). Gene expressions were normalized by *18S rRNA*. Data are represented as mean ± SD, paired Student's *t*-test was used and as relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a p*-value* \<0.05 (\*), p*-value* \<0.005 (\*\*). (**F**) *Pitx2* expression analysis by whole-mount ISH in Wt and *Rab23^-/-^* calvaria at E15.5. Arrows indicate *Pitx2* overexpression in the lambdoid suture. pb: parietal bone, ipb: interparietal bone, ls: lambdoid suture. Scale bar: 500 µm. (**G**) RT-qPCR expression analysis of *Fgfr1b, Fgfr2b* and *Fgfr2c* mRNA from E15.5 Wt and *Rab23^-/-^* lambdoid suture reveals *Fgfr1b* overexpression in *Rab23^-/-^* sample (n = 8 for each genotype). Gene expressions were normalized by *18S rRNA*. Data are represented as mean ± SD, paired Student's *t*-test was used and relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a *P-value *\<0.05 (\*). (**H, I**) Western blotting of proteins extracted from Wt and *Rab23^-/-^* lambdoid suture at E15.5 (**H**) and relative intensity measurement (**I**) reveals over expression of FGFR1 in the *Rab23^-/-^* lambdoid suture (n = 6 for each genotype). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a p*-value *\<0.05 (\*). (**J**) Exogenous FGF10 treatment for 3 hr on Wt calvaria derived (CD) cells and subsequent *Fgfr1b and Fgfr2b* mRNA analysis by q-PCR shows induction of *Fgfr1b* expression in FGF10 treated cells compare to untreated Wt CD cells (n = 3 for each genotype). Gene expressions were normalized by *18S rRNA*. Data are represented as mean ± SD, paired Student's *t*-test was used and relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a *P-value*.](elife-55829-fig2){#fig2}

FGF10-induced upregulation of *Fgfr1b* expression in *Rab23^-/-^* lambdoid suture {#s2-4}
---------------------------------------------------------------------------------

We assessed the expression of FGF10-specific receptors *Fgfr1b, Fgfr2b,* also *Fgfr2c* in Wt and *Rab23^-/-^* lambdoid sutural mesenchymal tissue. Our analysis showed elevated *Fgfr1b* expression and a non-significant upregulation of *Fgfr2b* in *Rab23^-/-^* samples ([Figure 2G](#fig2){ref-type="fig"}). FGFR1 protein levels were found to be elevated in *Rab23^-/-^* lambdoid sutures compared to Wt samples when analyzed by western blotting ([Figure 2H,I](#fig2){ref-type="fig"}) and by immunohistochemical staining ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The expression of *Fgfr2c* was unchanged ([Figure 2G](#fig2){ref-type="fig"}). To test whether the upregulation of *Fgfr1b* and *Fgfr2b* expression was due to the high levels of FGF10 ligand present in the *Rab23^-/-^* lambdoid suture, we isolated E15.5 wild-type calvaria derived (CD) mesenchymal cells and treated them with exogenous FGF10 (250 ng/ml) for 3 hr. *Fgfr1b* and *Fgfr2b* expression levels were then assessed by RT-qPCR. We found a significant (p=0.05) upregulation of *Fgfr1b* expression and a slight upregulation of *Fgfr2b* expression in the cultured CD mesenchymal cells after exogenous FGF10 stimulation, indicating FGFR1b as a target of FGF10 in the calvarial mesenchyme ([Figure 2J](#fig2){ref-type="fig"}).

Opposing MAPK-RUNX2 and Hh-GLI1 signaling in *Rab23^-/-^* lambdoid suture {#s2-5}
-------------------------------------------------------------------------

FGF signaling has been shown to activate MAPK signaling pathway subtypes pERK and p38 in suture morphogenesis and osteoblast differentiation ([@bib30]; [@bib48]; [Figure 3A](#fig3){ref-type="fig"}). In *Rab23^-/-^* lambdoid suture, we found decreased p38 and elevated pERK1/2 and RUNX2 expressions compare to Wt samples ([Figure 3B--G](#fig3){ref-type="fig"}). To test whether the upregulation of RUNX2 expression was due to the high levels of FGF10 present in the *Rab23^-/-^* lambdoid suture, we isolated E15.5 *Rab23^-/-^* calvaria derived (CD) mesenchymal cells and treated them with exogenous FGF10 (500 ng/ml) for 2 and 4 hr. *Runx2* expression levels were then assessed by RT-qPCR. We found a significant (p\<0.05) upregulation of *Runx2* expression at both time points compare to untreated samples, indicating that RUNX2 as a target of FGF10 in the calvarial mesenchyme ([Figure 3H](#fig3){ref-type="fig"}). Since ERK1/2 signaling regulates Hh and GLI expression, and RAB23 is a known negative regulator of Hh signaling ([@bib8]), we further assayed *Hh*, *Gli1, Gli2,* and *Gli3* transcripts extracted from Wt and *Rab23^-/-^* lambdoid sutural mesenchyme at E15.5. We detected a dramatic increase in the expression of *Hh* ([Figure 3I](#fig3){ref-type="fig"}) and *Gli1* ([Figure 3J](#fig3){ref-type="fig"}), a sutural stem cell marker ([@bib75]). Although *Gli3* expression is not changed, a functional change in the ratio of GLI3FL to GLI3R may still possible ([@bib67]). As TGFβ-superfamily members have also been shown to regulate suture patency ([@bib28]; [@bib29]; [@bib47]), we assayed both pSMAD1/5/8 and pSMAD2/3 expressions but found no difference between Wt and mutant samples ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

![Analysis of MAPK signaling in Wt and *Rab23^-/-^* lambdoid suture.\
(**A**) Represents two downstream pathway subtypes p38 and ERK of MAPK signaling involve in RUNX2 activation and suture fusion. (**B, C**) Western blotting analysis of pERK44/42 and α-ERK44/42 protein levels extracted from Wt and *Rab23^-/-^* lambdoid suture at E15.5 (**B**) and relative intensity measurement (**C**) shows higher pERK44 and pERK42 levels in *Rab23^-/-^* lambdoid suture (n = 6 for each genotype). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a *P-value* \<0.05 (\*). (**D, E**) Western blotting analysis of phospho-p38 and p38 protein levels extracted from Wt and *Rab23^-/-^* lambdoid suture at E15.5 (**D**) and relative intensity measurement (**E**) shows lower phospho-p38 and p38 levels in *Rab23^-/-^* lambdoid suture (n = 6 for each genotype). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a p*-value* \<0.05 (\*), p*-value* \<0.005 (\*\*). (**F, G**) Western blotting analysis of RUNX2 protein level extracted from Wt and *Rab23^-/-^* lambdoid suture at E15.5 (**F**) and relative intensity measurement (**G**) shows higher RUNX2 level in *Rab23^-/-^* lambdoid suture (n = 6 for each genotype). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a p*-value* \<0.05 (\*). (**H**) *Runx2* expression analysis by RT-qPCR in exogenous FGF10 treated (500 ng/ml) and untreated *Rab23^-/-^* calvaria derived cells at 2 and 4 hr. (n = 3 for each genotype). Gene expressions were normalized by *18S rRNA*. Data are represented as mean ± SD, paired Student's *t*-test was used and relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a *P-value* \<0.05 (\*), *P-value* \<0.005 (\*\*). (**I, J**) RT-qPCR expression analysis of hedgehog signaling components *Hh* (**H**), *Gli1*, *Gli2* and *Gli3* (**I**) in the Wt and *Rab23^-/-^* lambdoid suture reveals overexpression of *Hh* and *Gli1* in *Rab23^-/-^* lambdoid suture (n = 8 for each genotype). Gene expressions were normalized by *18S rRNA*. Data are represented as mean ± SD, paired Student's *t*-test was used and relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a *P-value* \<0.05 (\*), *P-value* \<0.005 (\*\*). n.s: non-significant.](elife-55829-fig3){#fig3}

*Rab23^-/-^* lambdoid suture and MEF cells show increased osteoprogenitor cell proliferation {#s2-6}
--------------------------------------------------------------------------------------------

As FGF10-pERK1/2 signaling and RUNX2 are known to regulate suture osteoprogenitor proliferation ([@bib28]; [@bib50]), we assessed co-expression of EdU and RUNX2 in the WT and *Rab23^-/-^* lambdoid suture. EdU and RUNX2 co-localized in the osteogenic fronts indicating that the proliferating cells are osteoprogenitors ([Figure 4A,B](#fig4){ref-type="fig"}). We analyzed the proliferation in Wt and *Rab23^-/-^* lambdoid sutures ([Figure 4C--H](#fig4){ref-type="fig"}). EdU pulsed *Rab23^-/-^* samples showed more proliferating cells in the osteogenic fronts compared to Wt ([Figure 4C--H](#fig4){ref-type="fig"}). In addition, increased level of cell proliferation was observed in *Rab23^-/-^* derived mouse embryonic fibroblast (MEF) cells ([Figure 4I](#fig4){ref-type="fig"}). *Rab23^-/-^* calvaria derived cells also had an elevated number of total cells at different passages (P^1^ to P^3^) when compared to Wt calvaria derived cells ([Figure 4J](#fig4){ref-type="fig"}). Increased proliferation in the sutures can result in a larger pool of osteoprogenitor cells and enhanced osteogenesis ([@bib31]; [@bib52]). Taken together, this data shows that RAB23 is needed to repress proliferation in undifferentiated mesenchymal cells.

![Cell proliferation analysis in Wt and *Rab23^-/-^* lambdoid sutural cells and MEF cells.\
(**A--H**) EdU pulsed assay in the Wt and *Rab23^-/-^* lambdoid sutures at E17.5 shows proliferating cells in red color (**A--F**). Proliferating cells show co-localization with osteoprogenitor and osteoblast marker RUNX2 (green) in the osteogenic front (inset, white arrow) in both Wt and *Rab23^-/-^* lambdoid suture (**A, B**). Analysis of EdU pulsed cells (**C--F**) together with nuclear staining (**E, F**) in the Wt and *Rab23^-/-^* lambdoid suture and subsequent quantification revealed that *Rab23^-/-^* sutures show higher cell proliferation as percentage of EdU-positive cells compare to total cells (**G**) and percentage of EdU-positive cells only (**H**) in those sutures are higher compare to Wt samples (n = 4 for each genotype). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a *P*-value \<0.005 (\*\*). pb: parietal bone, ipb: interparietal bone, ls: lambdoid suture, of: osteogenic front. Scale bar: 100 µm. (**I**) EdU incorporation in the cultured Wt and *Rab23^-/-^* MEF cells isolated from E13.5 embryos show 8--15% more cell proliferation (DNA duplication) in *Rab23^-/-^* samples compare to corresponding Wt samples (n = 3 for each genotype). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a p*-value* \<0.05 (\*). (**J**) Represents passaging (P^1^ to P^3^ ) of Wt and *Rab23^-/-^* calvaria derived primary cells in the culture show the total number of *Rab23^-/-^* cells (ml^−1^) in each passage increases more rapidly than Wt cells, while the cell viability (determined by trypan blue) and cell size were similar in all cell lines. (n = 3 for each genotype). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a p-value \<0.005 (\*\*), p*-value* \<0.001 (\*\*\*).](elife-55829-fig4){#fig4}

RAB23 regulates suture patency through a MEK-driven mechanism {#s2-7}
-------------------------------------------------------------

Our data suggest that *Rab23^-/-^* lambdoid suture undergoes fusion through aberrant FGF signaling, specifically by activating pERK1/2 signaling, RUNX2 and enhanced cell proliferation of osteoprogenitor cells. To test this, we aimed to normalize the *Rab23^-/-^* lambdoid suture by inhibiting the activation of MEK1/2, a downstream component of the MAPK-ERK1/2 signaling pathway by using MEK1/2 inhibitor U0126. We cultured E18.5 Wt and *Rab23^-/-^* whole calvaria in osteogenic growth medium up to 72 hr. To confirm that lambdoid sutures were patent at time point zero, the vital bone dye calcein green was used to detect the bone edges. Calcein green was administered to pregnant females 24 hr before samples were taken. Half of the *Rab23^-/-^* calvaria were treated with U0126 and half of the *Rab23^-/-^* calvaria samples were untreated ([Figure 5A,B](#fig5){ref-type="fig"}). None of the untreated *Rab23^-/-^* (n = 0/12) and 84.34% of U0126 treated *Rab23^-/-^* (n = 11/12) lambdoid sutures were rescued ([Figure 5A,B](#fig5){ref-type="fig"}). To confirm whether bones were fused or not, Wt, U0126 treated and untreated *Rab23^-/-^* samples were further analyzed in tissue sections and by µ-CT ([Figure 5A--C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [Figure 5---Videos 1](#fig5video1){ref-type="video"}--[3](#fig5video3){ref-type="video"}). None of the Wt lambdoid sutures were fused (n = 0/12). The same experiment (n = 4 in each genotype) was carried out with E17.5 samples and cultured for 4 days. Untreated *Rab23^-/-^* lambdoid sutures underwent suture fusion by day 4, while U0126-treated *Rab23^-/-^* lambdoid sutures remained patent during the culture period ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). The effect of U0126 on sutural cells was also analyzed by cell death assay and no effect was observed in U0126-treated lambdoid sutural cells ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). U0126 treatment not only prevented suture fusion but it also normalized the level of osteoprogenitor cell proliferation ([Figure 5D--G](#fig5){ref-type="fig"}). EdU incorporation revealed that U0126 treated *Rab23^-/-^* lambdoid sutures (n = 8) exhibited reduced proliferation when compared to *Rab23^-/-^* controls (n = 8) ([Figure 5D--G](#fig5){ref-type="fig"}) and normalized it to Wt levels (n = 8) after 24 hr of culture ([Figure 5D,E](#fig5){ref-type="fig"}). The proliferation in all genotypes decreased over time ([Figure 5D--G](#fig5){ref-type="fig"}). This indicates that RAB23 regulates suture patency through a MAPK-MEK-ERK-driven mechanism. pERK1/2 regulates RUNX2 and GLI1 expression in calvaria derived mesenchymal cells.

![Rescuing *Rab23^-/-^* lambdoid suture fusion with pERK1/2 inhibitor.\
(**A--C**) In vivo calcein green incorporation followed by in vitro calvaria culture in osteogenic medium and adding alizarin red in medium allowed to follow the bone growth in the sutural site. Layout of lambdoid suture rescue study (**A**). E18.5 Wt and a double number of *Rab23^-/-^* calvaria were cultured in vitro for 3 day. Half of the *Rab23^-/-^* calvaria were taken for control (DMSO) treatment and the other half were treated with ERK1/2 inhibitor U0126. 100% of *Rab23^-/-^* control sutures are fused by day 3 of culture (A, B, alizarin red bone staining and C, µ-CT images) while 83.34% of *Rab23^-/-^* suture with U0126 treated shows no fusion (**A, B**). \# indicates dropout of two samples from each group due to technical hindrance. Dotted lines indicate bone edge. pb: parietal bone, ipb: interparietal bone. Scale bar: 500 µm (**B, C**). (**D--G**) Represents EdU incorporation in the E18.5 calvaria after 24 hr and 48 hr of culture. EdU was added in the culture medium for additional 2 hr and cell proliferation analyzed in the sectioned Wt, control *Rab23^-/-^* and U0126 treated *Rab23^-/-^* lambdoid sutural samples (**D, F**). U0126 reduced the cell proliferation in *Rab23^-/-^* samples compare to untreated *Rab23^-/-^* samples at 24 hr and 48 hr. U0126 treated *Rab23^-/-^* suture shows dramatic reduction of cell proliferation compare to untreated *Rab23^-/-^* suture (**D, E**). The reduction of cell proliferation has shown consistent at 48 hr (**F, G**) (n = 8 for each genotype). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a p-value \<0.05 (\*), p-value \<0.005 (\*\*), p-value \<0.001 (\*\*\*). Scale bar: 200 µm (**D, F**).](elife-55829-fig5){#fig5}

We analyzed the effect of the MEK1/2 inhibitor U0126, cyclopamine and the combined action of cyclopamine and U0126 on pERK1/2, RUNX2 and GLI1 expression levels in *Rab23^-/-^* CD cells at 6, 24 and 48 hr of culture ([Figure 6](#fig6){ref-type="fig"}). After 6 hr of culture, the relative pERK1/2 levels were significantly reduced in U0126-treated *Rab23^-/-^* cells compare to untreated *Rab23^-/-^* cells. The downregulation of pERK1/2 continued in U0126-treated *Rab23^-/-^* cells at 24 and 48 hr of culture compare to the untreated *Rab23^-/-^* cells ([Figure 6A,B](#fig6){ref-type="fig"}). Whereas, RUNX2 expression significantly reduced only after 48 hr of U0126-treated *Rab23^-/-^* cells ([Figure 6A,C](#fig6){ref-type="fig"}). U0126-treated *Rab23^-/-^* cells showed gradual reduction of GLI1 expressions at 6 and 24 hr; however, it showed drastic reduction at 48 hr compared to untreated *Rab23^-/-^* cells ([Figure 6A,D](#fig6){ref-type="fig"}). Further immunohistochemical expression of GLI1 was also found reduced in the U0126 treated *Rab23^-/-^* lambdoid sutures at 24 and 48 hr compared to untreated *Rab23^-/-^* lambdoid sutures ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). The effect of cyclopamine and combined action of cyclopamine and U0126 on these cells showed that cyclopamine has no effect on pERK1/2 expression and can reduce RUNX2 expression only after prolonged exposure (48 hr) ([Figure 6E-H](#fig6){ref-type="fig"}). However, the combined action of cyclopamine and U0126 caused a rapid downregulation of RUNX2 (24 hr) ([Figure 6E-H](#fig6){ref-type="fig"}). These findings collectively indicate that pERK1/2 regulates RUNX2 and GLI1 expressions. Whereas, RUNX2 is a predominant downstream target of pERK1/2 and a weak target of GLI1.

![RUNX2 and GLI1 are downstream target of pERK1/2.\
(**A--D**) Time-dependent effect of U0126 in regulating pERK1/2, RUNX2 and GLI1 expressions has been analyzed by western blotting in the proteins extracted from E15.5 *Rab23^-/-^* CD cells. These cells were treated with or without U0126. Relative pERK1/2 levels in *Rab23^-/-^* CD cells are drastically reduces upon U0126 exposure at 6 hr and also shows downregulation of pERK1/2 at 24 and 48 hr upon U0126 exposure compare to corresponding untreated *Rab23^-/-^* CD cells (**A, B**). RUNX2 expression significantly reduces in *Rab23^-/-^* CD cells only after 48 hr of U0126 exposures (**A, C**). GLI1 expression in *Rab23^-/-^* CD cells sequentially downregulated upon U0126 exposures at 6, 24 and 48 hr (**A, D**) (n = 3 blots for each time points). (**E--H**) Time-dependent effect of cyclopamine (10 µM) and combined effect of cyclopamine (10 µM) and U0126 (5 µM) in regulating GLI1, pERK1/2, and RUNX2 expressions has been analyzed by western blotting in the proteins extracted from E15.5 *Rab23^-/-^* CD cells. These cells were treated with or without cyclopamine and combined cyclopamine and U0126 for 6, 24 and 48 hr. Relative GLI1 levels are significantly reduces at every time points upon cyclopamine treatment and show further gradual reduction of GLI1 upon combined treatment of cyclopamine with U0126 (**E--H**). Relative pERK1/2 levels in *Rab23^-/-^* CD cells are drastically reduces upon combined cyclopamine and U0126 exposure at 6 hr (**E, F**) and also shows downregulation of pERK1/2 at 24 and 48 hr upon combined cyclopamine and U0126 exposure compare to corresponding untreated *Rab23^-/-^* CD cells (**E, G, H**). However, pERK1/2 level remain unchanged at every time points upon cyclopamine treatment alone. RUNX2 expression significantly reduces in *Rab23^-/-^* CD cells after 24 hr by combined treatment of cyclopamine and U0126 (**E, G, H**), and only significantly reduces after 48 hr upon cyclopmine treatment alone. (n = 3 blots for each time points). Data represented as mean ± SD, paired Student's *t*-test was used. Statistical significance was defined as a p-value \<0.05 (\*), p-value \<0.005 (\*\*), p-value \<0.001 (\*\*\*).](elife-55829-fig6){#fig6}

Discussion {#s3}
==========

The calvarial suture allows us to study many developmental processes that regulate osteogenesis and skull morphogenesis. Normal development is ensured by the correct temporal and spatial coordination of skeletal patterning, mesenchymal stem cell niche regulation, condensation formation, osteoprogenitor expansion, and osteoblast differentiation and function. In this study, we generated *Rab23-*deficient mice that survive into late gestation and they exhibit multiple suture craniosynostosis. We show that RAB23 regulates the sutural stem cell niche marker GLI1, represses Hh, and inhibits osteoprogenitor expansion. RAB23 also represses FGF10-driven pERK1/2 signaling which has the multiple effect of directly regulating osteoprogenitor development, RUNX2-mediated differentiation and of repressing GLI1. Therefore, RAB23 coordinates suture biogenesis by regulating FGF-ERK1/2-RUNX2 activity, as well as the activation of GLI1. In an attempt to study complex developmental events, we have utilized both primary cells and organ culture approaches. However, one can also take a more cell biological approach using immortalized cells remote from the external factors and by using this standardized approach it may be easier to understand the effects of a specific intervention. This will be help deciphering the role of RAB23, specifically during endocytosis.

FGF10 signaling regulates early osteogenesis: it is expressed in the osteogenic condensation, and is implicated in the pathogenesis of several craniosynostotic models ([@bib63]; [@bib65]). Here, we show that *Fgf10,* its receptor FGFR1b and the FGF activator *Pitx2*, are all upregulated in *Rab23-*deficient calvaria. It is surprising that the FGFR1b splice form, which is normally expressed in epithelia, is upregulated in the mesenchymal suture. However, this is not without precedent. While FGFRc isoforms are predominantly expresses in the mesenchyme and b isoforms in the epithelium, their expression is not mutually exclusive and FGFR1b is known to be expressed by late embryonic murine lung mesenchymal cells and also in the zebrafish in the sutural mesenchyme ([@bib2]; [@bib52]; [@bib53]; [@bib60]). Under pathological/force conditions, mis-expression of splice forms can occur. Occasionally, Apert craniosynostosis syndrome is caused by heterozygous Alu-insertions or large deletions in the FGFR2c domain. These rare mutations induce abnormal expression of the FGFR2b splice form alongside FGFR2c splice form in mesenchymal cells. This permits cells to respond to both b- and c-activating FGF ligands including FGF10 ([@bib3]; [@bib44]). Analyzing the MAPK pathway in *Rab23^-/-^* lambdoid sutures we show that p38 signaling is decreased and pERK1/2 increased. FGFR activation of pERK1/2 is important for several stages of osteoblastogenesis, including osteoprogenitor proliferation, and in the induction and stabilization of RUNX2 ([@bib6]; [@bib72]). Augmentation of pERK1/2 signaling either through overactivation of *FGFRs*, downregulation of its inhibitors, or downregulation of *ERF* that regulates the export of pERK from the nucleus, all result in craniosynostosis ([@bib35]; [@bib36]; [@bib59]; [@bib61]).

Although RUNX2 is a substrate for both p38 and pERK1/2, pERK1/2 can activate RUNX2 on average six times more efficiently than p38 ([@bib14]). In addition, ERK1/2 binding to RUNX2 through MAPK D site has greater affinity than p38 binding and more sensitive to osteoblast differentiation during calvaria explant or primary osteoblast culture ([@bib12]; [@bib14]). The importance of pERK1/2 regulation of RUNX2 during osteogenesis is shown in this study by the reversal of the craniosynostotic phenotype in *Rab23^-/-^* mice. p38 has been implicated in the skull phenotypes of craniosynostotic mice where it may regulate the development and growth of cartilage elements ([@bib69]; [@bib70]). Opposing roles of MAPK pathway subtypes p38 and pERK1/2 in cartilage development are well documented ([@bib39]; [@bib43]; [@bib58]).

Commonality of etiological mechanisms is suggested by the overlapping skeletal phenotypes exhibited in Carpenter syndrome and Grieg cephalopolysyndactyly syndrome patients as well as their mouse disease models, *Gli3^Xt−J/Xt−J^* ([@bib54]) and *Rab23^-/-^* (this study). Specifically, postaxial polydactyly in the forelimb, preaxial polydactyly in the hindlimb and lambdoid and interfrontal suture craniosynostosis ([@bib8]; [@bib23]; [@bib26]; [@bib68]). Collectively suggest that craniosynostosis and polysyndactyly are overlapping phenotypes of aberrant FGF and Hh signaling. Aberrant osteogenesis and suture obliteration in the *Gli3^Xt−J/Xt−J^* mouse is caused by concomitant derepression of GLI3 and augmentation of IHH which activates the osteogenic master regulatory transcription factor RUNX2 ([@bib67]). Analysis of early *Rab23^-/-^* embryos suggests that RAB23 also has a role in promoting the production of GLI3 repressor ([@bib9]). In both *Gli3^Xt−J/Xt−J^* and *Rab23^-/-^* calvaria elevated Hh signaling results in an upregulation of the transcription factor Gli1, and presumably the mesenchymal stem niche which it labels.

Previously, we have shown that FGF10 upregulates *Hh* and its receptor *Patch1* during facial development ([@bib53]). Here, we show FGF10 upregulates Runx2. Our study revealed that inhibition of pERK1/2 prevented *Rab23^-/-^* lambdoid suture fusion by decreasing osteoprogenitor proliferation and GLI1 expression ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). We further showed that combined and individual inhibition of GLI1 and pERK1/2 in *Rab23^-/-^* calvarial cells downregulated RUNX2 and GLI1 ([Figure 6](#fig6){ref-type="fig"}) and that this effect was exaggerated in *Rab23^-/-^* cells. Phenotypic analyses of compound *Rab23;Smoothened* early embryonic mice shows that RAB23 can regulate GLI independently of Smoothened ([@bib9]), and the regulation of GLI1 by pERK1/2 suggests a mechanism how this might occur ([Figure 7](#fig7){ref-type="fig"}). Non-canonical regulation GLI1 through tyrosine kinase activity has been documented during carcinogenesis, with activation of GLI1 promoting stemness through an increase in transcriptional activity, nuclear localization or protein stability ([@bib49]). However, the non-canonical repression of GLI1 has not been well described in a developmental context.

![Model: regulation of suture patency by RAB23.\
In the developing calvaria RAB23 regulates FGFR signaling by repressing FGF10 expression. This regulates the delicate balance of osteoprogenitor proliferation and differentiation. RAB23 also known as a negative regulator of Hh signaling. The regulation of GLI1 through ERK1/2 and Hh in the mesenchymal stem cell niche is maintained along with RUNX2 during osteoprogenitor proliferation and differentiation. Thus, through a combination of FGF and Hh signaling, RAB23 tightly synchronizes suture morphogenesis and patency.](elife-55829-fig7){#fig7}

We show that RAB23 represses both FGF and Hh/GLI signaling ([Figure 7](#fig7){ref-type="fig"}). RAB23 coordinates suture morphogenesis and controls suture patency through three mechanisms: FGF10-pERK1/2 signaling, the repression of Hh targets through a canonical pathway, and through the repression of GLI1 by pERK1/2. GLI1 contributes in the regulation of the mesenchymal stem cell niche. FGF10-pERK1/2 and also Hh-GLI1 signaling regulate osteoprogenitor cell proliferation.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species) or resource   Designation                               Source or reference            Identifiers                                                                                     Additional information
  ------------------------------------ ----------------------------------------- ------------------------------ ----------------------------------------------------------------------------------------------- -----------------------------
  Strain, strain background\           *Rab23opb2* mice C3Heb/FeJ                [@bib8]; [@bib27]                                                                                                              
  (*M. musculus*, C3Heb/FeJ)                                                                                                                                                                                    

  Strain, strain background\           *Rab23opb2* mice C57Bl/6                  This paper                                                                                                                     
  (*M. musculus*, C57/Bl6)                                                                                                                                                                                      

  Cell lines (*Mus musculus*)                                                    This paper                                                                                                                     

  Antibody                             Rabbit polyclonal RAB23                   Proteintech                    Cat\#11101--1-AP                                                                                WB: 1:1000, IHC: 1:250

  Antibody                             Rabbit monoclonal FGFR1                   Cell signaling technology      Cat\#9740                                                                                       WB: 1:1000, IHC: 1:250

  Antibody                             Rabbit monoclonal p44/42                  Cell signaling technology      Cat\#4965S                                                                                      WB: 1:1000

  Antibody                             Rabbit monoclonal phospho-p44/42          Cell signaling technology      Cat\#9101                                                                                       WB: 1:1000

  Antibody                             Rabbit monoclonal phospho-p38             Cell signaling technology      Cat\#4631S                                                                                      WB: 1:1000

  Antibody                             Rabbit polyclonal p38                     Cell signaling technology      Cat\#9212                                                                                       WB: 1:1000

  Antibody                             Rabbit monoclonal RUNX2                   Cell signaling technology      Cat\#8486                                                                                       WB: 1:1000, IHC: 1:250

  Antibody                             Mouse monoclonal GLI1                     Cell signaling technology      Cat\#2643                                                                                       WB: 1:1000, IHC: 1:250

  Antibody                             Rabbit monoclonal pSMAD2/3                Cell signaling technology      Cat\#8828                                                                                       WB: 1:1000

  Antibody                             Rabbit polyclonal pSMAD1/5/8              Millipore                      Cat\#AB3848                                                                                     WB: 1:1000

  Antibody                             Mouse monoclonal RUNX2                    Santa Cruz Biotechnology       Cat\# sc-390351                                                                                 WB: 1:1000, IHC: 1:250

  Antibody                             Mouse αTubulin                            Sigma-Aldrich                  Cat\#T6199                                                                                      1:2000

  Antibody                             Goat anti-rabbit IgG (H+L), Alexa 488     Thermo Fisher Scientific       Cat\#A-11008                                                                                    1:500

  Antibody                             Goat anti-mouse IgG (H+L), Alexa 546      Thermo Fisher Scientific       Cat\#A-110003                                                                                   1:500

  Antibody                             Goat anti-mouse IgG (H+L), Alexa 488      Thermo Fisher Scientific       Cat\#A-11001                                                                                    1:500

  Antibody                             Goat anti-rabbit 680LT                    LI-COR                         Cat\#925--68021                                                                                 1:5000

  Antibody                             Goat anti-rabbit 800CW                    LI-COR                         Cat\#925--32211                                                                                 1:5000

  Antibody                             Goat anti-mouse IRDye 800CW               LI-COR                         Cat\#925--32210                                                                                 1:5000

  Commercial assay or kit              Enzmet HRP detection kit                  Nanoprobes                     Cat\#6001                                                                                       

  Commercial assay or kit              Hoechst 33342                             Thermo Fisher Scientific       Cat\# H3570                                                                                     1:2000

  Commercial assay or kit              Pierce IP lysis buffer                    Thermo Fisher Scientific       Cat\#87787                                                                                      

  Commercial assay or kit              RevertAid reverse transcriptase           Thermo Fisher Scientific       Cat\#EP0441                                                                                     

  Commercial assay or kit              Random hexamer primer                     Thermo Fisher Scientific       Cat\#SO142                                                                                      

  Commercial assay or kit              Ribolock RNase inhibitor                  Thermo Fisher Scientific       Cat\#EO0381                                                                                     

  Commercial assay or kit              Odyssey blocking buffer                   LI-COR                         927--40100                                                                                      

  Commercial assay or kit              FGF10                                     R and D                        Cat\#6224-FG-025                                                                                

  Commercial assay or kit              Complete protease inhibitor cocktail      Roche                          Cat\#04693116001                                                                                

  Commercial assay or kit              Complete phosphatase inhibitor cocktail   Roche                          Cat\#04906845001                                                                                

  Commercial assay or kit              Nucleospin RNA                            Biotop                         Cat\#740955.250                                                                                 

  Commercial assay or kit              Click-iT EdU Alexa Fluor 594              Invitrogen                     Cat\#C10339                                                                                     

  Commercial assay or kit              EdU (5-ethynyl-2´-deoxyuridine)           Sigma-Aldrich                  Cat\#A10044                                                                                     

  Commercial assay or kit              U0126                                     Sigma-Aldrich                  Cat\#662005                                                                                     

  Commercial assay or kit              Alizarin-3-methyliminodiacetic acid       Sigma-Aldrich                  Cat\#A3882                                                                                      

  Commercial assay or kit              Calcein green                             Sigma-Aldrich                  Cat\#C0875                                                                                      

  Commercial assay or kit              Apoptosis detection kit                   Abcam                          Cat\#ab206386                                                                                   

  Commercial assay or kit              Pierce BCA protein assay kit              Thermo Fisher Scientific       Cat\#23225                                                                                      

  Commercial assay or kit              KAPA SYBR FAST qPCR master mix (2X)       KAPA Biosystems                Cat\#KK4601                                                                                     

  Commercial assay or kit              4--20% Mini-PROTEAN TGX Gels              BIORAD                         Cat\#456--1094                                                                                  

  Sequence-based reagent               *Pitx2*                                   This study                     [NM_001286942.1](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=559098490)    *F: CCGCCTGGCAGTCACC*\
                                                                                                                                                                                                                *R: CTCCATTCCCGGTTATCGGC*

  Sequence-based reagent               *Fgf10*                                   This study                     [NM_008002.4](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=226823275)       F: AGGCTGTTCTCCTTCACCAAG\
                                                                                                                                                                                                                R:ATGTTATCTCCAGGACACTGTACG

  Sequence-based reagent               *Gli1*                                    This study                     [NM_010296.2](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=90186272)        *F: CAGCATGGGAACAGAAGGACT*\
                                                                                                                                                                                                                *R: CTCTGGCTGCTCCATAACCC*

  Sequence-based reagent               *Gli2*                                    This study                     [NM_001081125.1](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=124487480)    *F: AACTTTTGTCTCCTCGGGTCC*\
                                                                                                                                                                                                                *R: CTGCTGTCCTCCAAGAGACC*

  Sequence-based reagent               *Gli3*                                    This study                     [NM_008130.3](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=1447199263)      *F: AAGCCCATGACATCTCAGCC*\
                                                                                                                                                                                                                *R: CTCGAGCCCACTGTTGGAAT*

  Sequence-based reagent               *Hh*                                      This study                     [XM_006535649.4](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=1720412662)   *F: AAGCAGGTTTCGACTGGGTC*\
                                                                                                                                                                                                                *R: CCACGGAGTTCTCTGCTTTCA*

  Sequence-based reagent               *Fgfr1b*                                  [@bib34]                                                                                                                       *F: GGGAATTAATAGCTCGGATGA*\
                                                                                                                                                                                                                *R: ACGCAGACTGGTTAGCTTCA*

  Sequence-based reagent               *Fgfr2b*                                  This study                     [NM_201601.2](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=116089354)       *F: TCAAGGTCCTGAAGCACTCG*\
                                                                                                                                                                                                                *R: CAGCATCCATCTCCGTCACA*

  Sequence-based reagent               *Fgfr2c*                                  This study                     [NM_010207.2](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=116089348)       *F: AACCAGAAGAGCCACCAACC*\
                                                                                                                                                                                                                *R: TAGTCCAACTGATCACGGCG*

  Sequence-based reagent               *Runx2*                                   This study                     [NM_001271631.1](https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=410110933)    *F: CAGTCCCAACTTCCTGTGCT*\
                                                                                                                                                                                                                *R: CCCATCTGGTACCTCTCCGA*

  Sequence-based reagent               *18S rRNA*                                [@bib42]                                                                                                                       *F: AAACGGCTACCACATCCAAG*\
                                                                                                                                                                                                                *R: CAATTACAGGGCCTCGAAAG*

  Software                             Fiji (Image J)                            National Institute of Health   <https://fiji.sc/>                                                                              

  Software                             Desktop micro-CT system                   Bruker                         SkyScan1272                                                                                     

  Software                             Nrecon, Desktop micro-CT system           Bruker                         SkyScan1272                                                                                     

  Software                             Odyssey infrared imaging system           LI-COR Biosciences             Model 9120                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Study approval {#s4-1}
--------------

Animal experiments were approved by the University of Helsinki, Helsinki University Hospital and the Southern Finland Council Animal Welfare and Ethics committees. Permit ESAVI/11956/04.10.07/2017 (external) and KEK17-008 (internal).

Mice {#s4-2}
----

*Rab23^opb2/opb2^* (*Rab23^-/-^*) mice were originally in C3Heb/Fej background were crossed into C57Bl/6J mouse strain (Charles River) for six or more generations with speed congenic method. The animals for breeding were selectively based on highest amount of C57 SNP markers (Illumina mouse chip array) to speed up strain change. After four generations more than 89% of SNPs were on C57. The genotype of all mouse and embryos were verified with PCR-based genotyping as previously described ([@bib10]; [@bib27]).

Microarray and RT-qPCR {#s4-3}
----------------------

Analysis of the RNA expression was performed using Illuminan Mouse WG-6v2 microchips. RNA was isolated from E15 calvaria from *Rab23^-/-^* embryos and Wt littermates using Machrey-Nagel Nucleospin RNA II isolation kit. Labeling and chip run were performed by the Technology Centre, Institute for Molecular Medicine Finland (FIMM), University of Helsinki. The data analysis and normalization was performed using Chipster 3.16.0. Fold change of genes is calculated by arithmetic mean in linear scale and shown in the volcano plot. Fold change \>1 (up-regulated gene), fold change \< 1 (down-regulated gene). The microarray dataset has been deposited in MIAME-compliant GEO public database as source data. Accession number: GEO accession GSE140884. For quantitative PCR, RNA was isolated individually from whole calvaria and from lambdoid suture of *Rab23^-/-^* and Wt embryos at E15.5. 1 µg of RNA from calvarial (n = 3+3) and 500 ng of RNA from lambdoid suture (n = 8+8) were reverse-transcribed into cDNA using random hexamer primer and RevertAid reverse transcriptase (Thermo scientific). 2 µl of diluted cDNA and Brilliant III ultra-fast SYBR-green qPCR master mix with QuantiTect Primers (Qiagen).

RNAscope in situ hybridization {#s4-4}
------------------------------

We performed the experiments as previously described ([@bib57]). In single-gene in situ RNAscope transcripts appear in red. A customized 20ZZ probe named Mm-*Rab23* targeting 45--1330 of NM_008999.4 was purchased from Advanced Cell Diagnostics to perform *Rab23* expression analysis on mouse calvarial suture. Images were obtained using a bright field microscope (BX61, Olympus).

In situ hybridization on whole mounts {#s4-5}
-------------------------------------

In situ hybridizations on whole embryonic samples was performed using digoxigenin-UTP labeled *Rab23* probe and *Pitx2* probe according to the protocol and modification described ([@bib28]).

Immunohistochemistry {#s4-6}
--------------------

Immunohistochemistry on lambdoid sutural samples was performed using primary anti-RAB23, GLI1, RUNX2 and FGFR1 antibody. After incubation with HRP conjugated or alexa fluor conjugated secondary antibody Enzmet detection kit was used for GLI1 and FGFR1 detection and alexa fluor conjugated 488, 546 secondary antibody was used to detect RAB23 and RUNX2 signals. The samples were permeabilized by triton X-100 and antigen retrieval was performed by citrate buffer. All the other procedure was followed according to the protocol described ([@bib67]).

Isolation and culture of mouse calvaria derived primary cells {#s4-7}
-------------------------------------------------------------

WT and *Rab23^-/-^* embryos were taken out at E15.5 embryonic day. We and others have previously described the procedure of calvarial primary cells isolation ([@bib56]; [@bib67]). Cells were cultured in DMEM containing high glucose and supplemented with 10% FBS, glutamine, penicillin and streptomycin, maintained at 37°C with 5% CO~2~. After maintaining the isolated cells in growth medium next passage is always used for experiments.

Exogenous FGF10 treatment on calvaria derived mesenchymal cells {#s4-8}
---------------------------------------------------------------

E15.5 Wt calvaria derived mesenchymal cells were treated with exogenous FGF10 (250 ng/ml) for 3 hr. *Fgfr1b* and *Fgfr2b* mRNA expression were then assessed by RT-qPCR. E15.5 *Rab23^-/-^* calvaria derived mesenchymal cells were treated with exogenous FGF10 (500 ng/ml) for 2 and 4 hr. *Runx2* mRNA expression were then assessed by RT-qPCR.

Tissue lysis, protein extraction, quantification and western blotting {#s4-9}
---------------------------------------------------------------------

RIPA buffer containing 1% SDS together with protease inhibitor and phosphatase inhibitor were used to lyse the lambdoid sutural tissue on ice. After brief sonication (10 s, twice), tissue lysates were centrifuged at full speed for 10 min to collect the protein supernatant. By using BCA protein assay kit, protein concentrations were measured for immunoblotting analysis. Equal amount of proteins from wild type and RAB23 deficient cells were subjected to prepare to separate on SDS-PAGE under reduced gel electrophoresis (4--20% Mini-PROTEAN TGX Gels, Bio-Rad). After transferring to nitrocellulose membrane, membranes were blocked by odyssey blocking buffer at room temperature for 3 hr. Membranes were then incubated with corresponding primary anti-RAB23, anti-p38, anti-phospho-p38, anti-ERK, anti-pERK, anti-RUNX2, anti-pSMAD1/5/8, anti-GLI1, anti-FGFR1 and anti-Tubulin antibodies and kept overnight at 4°C. Fluorophore-conjugated corresponding IRdye goat anti-rabbit 680LT or CW800 or anti-mouse 800CW secondary antibodies were used at room temperature for 1 hr. α-Tubulin was used to normalize protein expressions. In vitro inhibition of pERK1/2 in *Rab23^-/-^* calvaria derived primary cells (E15.5) was performed by adding 5 µM of U0126 and 10 µM of cyclopamine for 6, 24 and 48 hr. Membranes were scanned using an Odyssey infrared imaging system (Odyssey; LI-COR Biosciences, model 9120). Band intensity was determined using ImageJ (NIH) software.

Craniosynostosis rescue study and microscopy {#s4-10}
--------------------------------------------

After removing skin and underneath brain calvaria from E18.5 Wt and *Rab23^-/-^* were cultured in an in vitro explant culture system. The calvaria was kept on top of the filter laid on metallic grid. The calvaria sample was supplemented with DMEM containing 10% FBS, dexamethasone, ascorbic acid and β-glyceraldehyde. *Rab23^-/-^* calvaria received 5 µM of U0126 treatment or DMSO as control. After 48 hr fresh medium and inhibitors were added. After 48 or 72 hr, samples were fixed with 4% PFA for subsequent analysis. For immediate calvarial bone and suture recognition vital bone dye calcein green was injected to mother mouse 1 day before the E17.5 or E18.5 embryo collection. Subsequent imaging in the culture was performed after alizarin red incorporation in the medium. Images were taken by Olympus SZX12 fluorescent microscope.

Skeletal staining {#s4-11}
-----------------

The Alcian blue-Alizarin red staining of E18.5 specimens was performed as previously described ([@bib51]). For analysis of calvarial bone and sutures images were captured using Analysis software (Soft Imaging System) and Olympus BX41 microscope and analyzed in Adobe Photoshop CS4.

MEF isolation {#s4-12}
-------------

Mouse embryonic fibroblasts (MEFs) were isolated from E13.5 embryos (noon of the vaginal plug detection day was considered E0.5). Briefly, embryos were collected to sterile PBS. The head, liver and spleen were removed and used for histology, RNA isolation or for genotyping. The remaining tissue was cut into smaller pieces and dissociated with gentle pipetting in 0.25% Trypsin-EDTA solution. After 10 min incubation, any larger tissue pieces were discarded and remaining cell suspension was plated with rich MEF medium into two T25 flasks per embryo. The medium was changed daily until first passaging at confluency.

The growth medium was DMEM, High Glucose, GlutaMAX (Gibco) supplemented with 10% FBS, 1x non-essential amino acids (Gibco), 20 mM Hepes pH 7.3 and 1x penicillin-streptomycin. The cells were subcultured when 90% confluent to 750,000 live cells/T75 flask and only passages 1--6 (active division) were used for EdU pulsed proliferation analyses. The cell density and viability was assessed with Trypan Blue and Countess automated cell counter (Invitrogen).

EdU pulsing and staining {#s4-13}
------------------------

Cell proliferation was assessed by prior EdU incorporation followed by EdU click reaction. The MEF cell lines were pulsed for 1 hr with 10 µM EdU (Molecular probes, Invitrogen) in DMSO dissolved to pre-warmed medium before distribution to cells for 1 hr EdU pulse and fixed with 4% paraformaldehyde. The EdU was detected with Click-iT EdU imaging kit, Alexa fluor 594 (Molecular probes, Invitrogen) according to manufacturer\'s instruction. The number of EdU positive cells was counted from three separate experiments from a minimum five different locations per cell line and compared to total cell number determined with Hoechst 33342 staining of nuclei.

The mice were pulsed with 0.05 mg/g (i.p.) EdU in PBS 2 hr collection of tissue. After sacrificing E17.5 embryonic lambdoid sutures were collected and fixed o/n with 4% paraformaldehyde, and processed for paraffin sections. Paraffin-embedded lambdoid sutures were sectioned 7 µm size. The sections were deparaffinized and stained with same Click-iT kit. EdU click reaction procedure in brief, sectional explants were deparaffinized by xylene and rehydrated by a gradient of ethanol series. After washing with 2 mg/ml glycine, sutural sections were permeabilized with 0.5% Triton X-100. After several washing in PBS, 10 µM EdU cocktail was used for click reaction for 30 min at dark room. After several PBS washing 5 µg/ml Hoechst was used for counter staining. Vectashield mounting medium was used to mount the slides. Slides were then imaged with fluorescence microscope with emission wavelength 615 nm.

Cell counting: Cluster of proliferating cells (red cell) considered as osteogenic front. The middle of the scale was kept on the tip of each osteogenic front and then rest of the part was flanked towards the suture. The length of the scale is 145 µm and width 61 µm. Cells from skin, dura mater and cartilage were not included in counting.

Apoptotic assay {#s4-14}
---------------

Apoptotic assay on tissue sections from in vitro cultured Wt, control *Rab23^-/-^* and U0126 treated *Rab23^-/-^* lambdoid suture was performed according to manufacturer protocol (In situ apoptosis detection kit AB206386).

X-ray micro computed tomography {#s4-15}
-------------------------------

E18.5 WT and *Rab23^-/-^* whole head and samples from rescue studies were collected and fixed with 4% paraformaldehyde overnight. Samples were dehydrated by gradient ethanol series to 70% (v/v), followed by processed for x-ray microtomography (µCT) imaging with Bruker SkyScan1272 (desktop micro-CT system, Bruker microCT N.V., Kontich, Belgium). Tomography 3D reconstructions were obtained using the program NRecon (desktop micro-CT system, Bruker microCT N.V., Kontich, Belgium).

Data analysis and statistics {#s4-16}
----------------------------

Paired student's *t-test* has been applied to perform the statistics of all the data obtained from measurements, western blotting and gene expressions. Data represented as mean ± SD. p-Value less than 0.05 considered as statistical significant.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The authors have effectively determined the mechanism underlying craniosynostosis caused by *Rab23* deletion and determined the function of RAB23 during intramembranous bone formation. Notably, RAB23 coordinates skull morphogenesis by regulating suture patency through FGF10-ERK1/2RUNX2 signaling, repressing *Hh* targets through a canonical pathway, and regulating the sutural stem cell marker GLI1.

**Decision letter after peer review:**

Thank you for submitting your article \"RAB23 coordinates early osteogenesis by repressing FGF10-pERK1/2-RUNX2 and GLI1\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Mone Zaidi as the Reviewing Editor and Clifford Rosen as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Nan Hatch (Reviewer \#1).

The reviewers have discussed the reviews with one another, and on basis of their recommendation, we are requesting a revised submission. In recognition of the fact that revisions may take longer than the two months we typically allow due to the COVID-19 pandemic, until the research enterprise restarts in full, we will give authors as much time as they need to submit revised manuscripts.

Summary:

The authors have generated and studied global *Rab23*^-/-^ mice at embryonic time points to establish an essential role for *Rab23* in skull growth and morphogenesis. These mice serve as a useful model for Carpenter Syndrome, features of which include craniosyntososis and dactyly. The current work address mechanism by integrating studies of developmental anatomy, gene expression, analysis of cell proliferation and pharmacological inhibition. While there was overall interest in the manuscript and its conclusions, significant concerns were raised regarding the approach, specifically arising from the absence of conclusive experiments.

Essential revisions:

1\) The authors do not take a cell biological approach to dissect the primary chain of events leading to the phenotypes they observe. Furthermore, the experimental results are based on collections of what are undoubtedly highly heterogeneous cell types, namely whole calvaria, cultured calvaria-derived mesenchymal cells, dissected and cultured lambdoid sutures, making it impossible to distinguish primary from secondary events in the chain of pathophysiology. This aspect needs clarification.

2\) Stronger rationale should be provided earlier in the manuscript explaining why FGF10 and PITX2 were the genes chosen to study the differentially expressed genes. The same could be said for *Hh* and GLI1 expression. The manuscript would benefit from cluing in the reader earlier on regarding rationale for studying these specific factors in their study. Additionally, there is review concern that there is no other evidence for the direct regulation of these molecules by RAB23, and given the caveats above (point 1), secondary mechanisms for these effects are entirely possible. This aspect needs clarification. Furthermore, there is a paucity of robust evidence of the functional significance of any of these molecules in suture fusion. Changed expression levels of any given gene does not necessarily establish its role in a phenotype. The authors should examine in loss- or gain-of-function experiments the functionality of what they consider as the most critical disease-causing gene or gene set.

3\) The authors checked premature suture fusion either by CT scanning or alizarin red-alzarin blue staining. Histological analysis, or at least coronal/sagittal sections of the suture CT images, are necessary to confirm the suture fusion. Furthermore, they need to co-stain markers, such as ALP and RUNX2, with their RNAscope analyses (e.g. Figure 1P, middle panel) and immunofluorescence staining images. It is currently difficult to differentiate the suture mesenchyme from the bone at these embryonic stages, which makes data interpretation difficult. Finally, to provide evidence for their conclusion that *Rab23* lambdoid suture and MEF cells show increased osteoprogenitor cell proliferation, the authors must to co-localize Edu with osteoprogenitor cell markers in vivo, noting that Edu will label all proliferating cells.

4\) There is no supporting data for a downstream action of FGF10 although both FGF10 and PITX2 are increased in *Rab23*^-/-^ mice. The authors have only validated the in situ expression of *Pitx2*, not of *Fgf10*. There is published data showing that PITX2 is an upstream regulator of FGF10 during early organogenesis of other tissues. Data showing that FGF10 is downstream of PITX2 in suture development is therefore required to strengthen the conclusion.

5\) The authors noted an elevated expression of FGF10 and FGFR1b in *Rab23*^-/-^ mice, and concluded that increased FGFR1b was induced by FGF10. There is however the possibility that increased FGFR1b is a direct result of the *Rab23* mutation. This possibility needs to be discussed or excluded experimentally.

6\) The authors found elevated pERK1/2, RUNX2, *Hh* and GLI1, as well as decreased p38 in *Rab23*^-/-^ mice. It however remains unclear whether the elevated pERK1/2 and pp38 are secondary to FGF signaling, and whether *Hh* and GLI1 upregulation is caused by phosphorylation of ERK1/2. Interestingly, published data shows that RAB23 can negatively regulate the *Hh* pathway directly. Therefore, it is critical to experimentally establish a direct role for RAB23 in changing gene expression. Promoter-reporter assays could be useful in this regard.

7\) The authors used pSmad1/5/8 to test whether the TGF-β superfamily was affected by the *Rab23* mutation. Since pSmad1/5/8 is the readout of global BMP signaling, another readout of the TGF signaling pathway, pSmad2/3, should be tested.

8\) It is surprising that the epithelial, but not mesenchymal splice forms of FGFR1 are upregulated in suture and/or calvarial tissue. The authors should make some attempt to explain as to how or why this is the case if the sample should only contain mesenchymal cells.

10.7554/eLife.55829.sa2

Author response

> Essential revisions:
>
> 1\) The authors do not take a cell biological approach to dissect the primary chain of events leading to the phenotypes they observe. Furthermore, the experimental results are based on collections of what are undoubtedly highly heterogeneous cell types, namely whole calvaria, cultured calvaria-derived mesenchymal cells, dissected and cultured lambdoid sutures, making it impossible to distinguish primary from secondary events in the chain of pathophysiology. This aspect needs clarification.

We thank the reviewers for bringing up this point. We agree that to understand the primary role of RAB23 direct cell biological investigations are needed. Although the direct cellular roles of most RABs are known, very little is understood about RAB23, i.e., role in endocytosis, vesicle formation, recycling and degradation. We agree that by using immortalized cells one can use a standardized approach in which it is easier to understand the effects of a specific intervention. We have added text to the manuscript to acknowledge and clarify these aspects.

It is true that suture morphogenesis and aberrant suture fusion can be investigated by cell biological approach. However, these developmental events are complex and a multiple-pronged strategy is also useful.

By not using such an approach you may bypass the real-time developmental events where multiple regulatory signaling pathways are highly orchestrated. These events regulate not only cell differentiation and function but also regulate tissue-tissue interactions, morphogenesis, patterning, boundary formation within the developing calvaria (Helms et al., 2005) (Twigg and Wilkie, 2015).

As the reviewers mentioned in this study we have combined many approaches (analysis of whole calvaria, cultured calvaria-derived mesenchymal cells, in vitro culture of dissected lambdoid sutures). It is true that some cellular heterogeneity may exist in the calvaria-derived mesenchymal cell cultures but during processing and after enzymatic digestion, epithelial cells, meningeal cells and cartilage cells are lost. Indeed this is a very well investigated, standard technique to harvest osteoblast progenitors (Lana-Elola et al., 2007; Liu et al., 2019; Malaval et al., 1999; Rodan and Noda, 1991)

We believe that by analyzing intact tissues and isolated cells we have provided a broad view of suture fusion in which location-specific information is maintained. Nevertheless, we do acknowledge that further analysis using a more cell biological approach will help in deciphering the role of RAB23, specifically during endocytosis.

> 2\) Stronger rationale should be provided earlier in the manuscript explaining why FGF10 and PITX2 were the genes chosen to study the differentially expressed genes. The same could be said for Hh and GLI1 expression. The manuscript would benefit from cluing in the reader earlier on regarding rationale for studying these specific factors in their study. Additionally, there is review concern that there is no other evidence for the direct regulation of these molecules by RAB23, and given the caveats above (point 1), secondary mechanisms for these effects are entirely possible. This aspect needs clarification. Furthermore, there is a paucity of robust evidence of the functional significance of any of these molecules in suture fusion. Changed expression levels of any given gene does not necessarily establish its role in a phenotype. The authors should examine in loss- or gain-of-function experiments the functionality of what they consider as the most critical disease-causing gene or gene set.

We thank the reviewers for these comments. Stronger rationale for why FGF signaling in particular, *Fgf10* and *Pitx2* were chosen to study further is now given early in the manuscript both in the Introduction section and in the Results section.

Most forms of syndromic craniosynostoses are caused by gain-of-function mutations in FGFR where the receptors exhibit ligand independent activation or lost the ligand binding specificity and bind with cognate ligand (Hajihosseini et al., 2009; Ibrahimi et al., 2001; Ibrahimi et al., 2004; Johnson and Wilkie, 2011; Yu et al., 2000). FGFRs isoforms show distinct FGF ligand binding affinity and biological functions. However, studies have shown that in Apert syndrome (FGFR2 mutation) mouse model FGFR2 isoform FGFR2c loses ligand specificity, and able to bind with cognate FGF10 (Hajihosseini et al., 2009; Ibrahimi et al., 2001; Ibrahimi et al., 2004; Johnson and Wilkie, 2011; Yu et al., 2000). Interestingly, genetic knockdown of *Fgf10* in this FGFR2 mutant mouse can rescue the premature suture fusion (Hajihosseini et al., 2009). FGF signaling pathway members have not been linked to RAB23-mediated trafficking. However, a study suggests that RAB23 resides in the plasma membrane and it is proposed to be involved in endocytosis (Evans et al., 2003). It has been shown that RAB23 transports dopamine receptors to the primary cilium (Leaf and Von Zastrow, 2015) and in this context, RAB23 might be involved in ligand-receptor turnover.

It was first evident that RAB23 is a negative regulator of hedgehog (*Hh*) signaling in mouse neural tube development (Eggenschwiler et al., 2001) and further studies showed that RAB23 negatively regulates GLI1 in Su(Fu) dependant manner in which RAB23 expression reduces nuclear localization of *Gli1* transcription factor (Chi et al., 2012). *Gli1* positive cells have been identified in the suture as the main source of mesenchymal stem cells and *Gli1* plays critical role in maintaining suture patency (Zhao et al., 2015). The above mentioned findings collectively encouraged us to unveil the role of RAB23 in regulating *Hh* and *Gli1* in suture biology.

We highly agree with the reviewers that secondary mechanisms for these effects are possible. To understand such effects, we have performed new experiments and the findings are presented in Figure 6 (Figure 6E-H) where we show that inhibition of hedgehog transducer SMO by cyclopamine could not alter pERK1/2, rather inhibition of pERK1/2 could downregulate GLI1. Primary effects of RAB23 acting as a small GTP-ase during vesicle trafficking may regulate the turnover of FGFR and thereby FGF signaling, but there is no direct evidence for this. We have clarified this in the manuscript. The Figure 6E-H is incorporated in revised manuscript along with previously shown Figure 6A-D.

We agree that there is little robust evidence for the fundamental significance of *Fgf10* and *Pitx2*. These, however, good evidence that FGF signaling, in general, is involved in suture fusion and are good evidence for the involvement of *Hh* signaling via *Gli1*. Mutation in several *Hh* pathway members including *Gli1* result in premature suture fusion (Twigg et al., 2016; Zhao et al., 2015).

We thank reviewer for suggesting us to examine loss- or gain-of-function experiments the functionality of what could be the most critical disease causing gene or gene set. We have performed additional experiments to understand this, our findings are presented in new figures (Figure 6E-H, Figure 3H, Figure 1P-c and Figure 4A-B). All these figures now incorporated in revised manuscript. Here we showed that abrogation of GLI1 and pERK1/2 by combined action of cyclopamine and U0126, and cyclopamine alone indicates that RUNX2 is the most critical gene that lies downstream of both pERK1/2 and GLI1 (Figure 6E-H). Co-staining of RAB23 and RUNX2 (Figure 1P-c) showed overlapped expression in the osteogenic front where the EdU positive cells are more prominent. Interestingly, EdU positive cells also showed overlapped signals with RUNX2 in the osteogenic front (Figure 4A-B). In addition, we showed that stimulation of RAB23 deficient cells by FGF10, overexpressed RUNX2 expression (Figure 3H). Here, we shown two ways of RUNX2 regulation: (1) overactivating the FGFR signaling and by (2) abrogating the pERK1/2 signaling. Our lab previously shown that RUNX2 is a downstream candidate of *Hh* signaling and critical regulator of suture patency and therefore, loss of one allele of RUNX2 in overactivation *Hh* signaling mouse model of craniosynostosis rescued from premature suture fusion (Tanimoto et al., 2012). Current study thus showed well synergies and drawn the network of RAB23, FGFR, *Hh* and RUNX2 signaling in suture biology.

> 3\) The authors checked premature suture fusion either by CT scanning or alizarin red-alzarin blue staining. Histological analysis, or at least coronal/sagittal sections of the suture CT images, are necessary to confirm the suture fusion. Furthermore, they need to co-stain markers, such as ALP and RUNX2, with their RNAscope analyses (e.g. Figure 1P, middle panel) and immunofluorescence staining images. It is currently difficult to differentiate the suture mesenchyme from the bone at these embryonic stages, which makes data interpretation difficult. Finally, to provide evidence for their conclusion that Rab23 lambdoid suture and MEF cells show increased osteoprogenitor cell proliferation, the authors must to co-localize Edu with osteoprogenitor cell markers in vivo, noting that Edu will label all proliferating cells.

We thank the reviewers for pointing out these important issues.

We have now provided a new figure, which confirms of coronal suture fusion in a micro-CT slice /section through the *Rab23*^-/-^ calvaria. We now incorporated this image into Figure 1 (Figure 1B-b, green arrow) in the revised manuscript.

In response to the co-stain marker issue, new immunohistochemical staining with RAB23 and RUNX2 has been carried out in Wt sections. Figure 1P-c shows RAB23 expression in the lambdoid suture (green) with RUNX2 co-stain marker (red). The figure shows RAB23 is expressed in the osteogenic front and RUNX2 is co-localized with RAB23 (yellow). The Figure 1P-c is incorporated in revised manuscript along with previously shown Rab23 RNAscope expression Figure 1P-b.

In response to whether the osteoprogenitor cells are proliferating we have now performed a RUNX2 immunohistochemistry on EdU-pulsed tissue sections (Wt and Rab23^-/-^). The new figure (Figure 4A-B) shows EdU-pulsed proliferating cells (red) in the Wt and Rab23 deficient sutures (E17.5) stained with osteoprogenitor marker RUNX2 (green). RUNX2 is co-localizes with EdU in the osteogenic front (yellow, white arrows) in both Wt and RAB23 deficient samples. The Figure 4A-B is incorporated in revised manuscript along with previously shown Figure 4C-J.

> 4\) There is no supporting data for a downstream action of FGF10 although both FGF10 and PITX2 are increased in Rab23^-/-^ mice. The authors have only validated the in situ expression of Pitx2, not of Fgf10. There is published data showing that PITX2 is an upstream regulator of FGF10 during early organogenesis of other tissues. Data showing that FGF10 is downstream of PITX2 in suture development is therefore required to strengthen the conclusion.

We highly appreciate reviewers' comments. Here a new figure (Figure 3H) added which indicating downstream action of FGF10. When RAB23 deficient cells were treated with or without FGF10 (500 ng/ml) for 2 and 4 hours followed by RT-qPCR analysis revealed FGF10 stimulation upregulates *Runx2* expression in both time points, indicating that *Runx2* is a downstream target of FGF10 signaling. The Figure 3H is incorporated in revised manuscript along with previously shown Figure 3.

In addition, we have now acknowledged in the manuscript text that we have not shown *Pitx2* regulation of FGF10 in the calvaria. Also, we downplayed this aspect by removing *Pitx2* from the schematic diagram (Figure 7). Hopefully, this improves the focus and clarifies the manuscript.

> 5\) The authors noted an elevated expression of FGF10 and FGFR1b in Rab23^-/-^ mice, and concluded that increased FGFR1b was induced by FGF10. There is however the possibility that increased FGFR1b is a direct result of the Rab23 mutation. This possibility needs to be discussed or excluded experimentally.

This is a good point. We agree with the possibility that RAB23 could directly regulate FGFR1b. RAB23 is localized to the plasma membrane and are proposed to be involved in endocytosis and growth factor receptor recycling and turnover, and therefore, availability for ligand binding at the cell surface (Evans et al., 2003). This issue is now discussed in the Introduction and Discussion.

> 6\) The authors found elevated pERK1/2, RUNX2, Hh and GLI1, as well as decreased p38 in Rab23^-/-^ mice. It however remains unclear whether the elevated pERK1/2 and pp38 are secondary to FGF signaling, and whether Hh and GLI1 upregulation is caused by phosphorylation of ERK1/2. Interestingly, published data shows that RAB23 can negatively regulate the Hh pathway directly. Therefore, it is critical to experimentally establish a direct role for RAB23 in changing gene expression. Promoter-reporter assays could be useful in this regard.

We appreciate this point. We agree that these aspects should be clarified. To test whether GLI1 upregulation is caused by phosphorylation of ERK1/2 alone, we used the SMO inhibitor cyclopamine to block canonical *Hh* signaling and also U0126 to block ERK1/2 (Individually and in combination with cyclopamine) in *Rab23*^-/-^ cells. New Figure 6A-H shows that U0126 and cyclopamine both individually can downregulate GLI1. This indicates that GLI1 is regulated through both canonical *Hh* signaling and also indirectly through pERK1/2. Cyclopamine did not downregulate pERK1/2, indicating that GLI1 resides downstream of pERK1/2.

The reviewers state that published data shows that RAB23 can negatively regulate the *Hh* pathway directly. Therefore, it is logical that the increased level of GLI1 in RAB23 mutant cells can in part be corrected by blocking canonical *Hh* signaling. Our investigation further unveiled that RUNX2 is downstream of both pERK1/2 and GLI1 (Figure 6E-H). These experiments combined with the data from Figures 2 and 3 establish a role for RAB23 in changing gene expression of FGF/MAPK signaling, *Hh*/GLI1 signaling and the osteoblast master regulator RUNX2. This data is also consistent with the findings that GTP bound block form of RAB23 reduces nuclear localization of GLI1 in hepatocellular carcinoma cell lines (Sun et al., 2012).

The Figure 6E-H is incorporated in revised manuscript along with previously shown Figure 6A-D.

> 7\) The authors used pSmad1/5/8 to test whether the TGF-β superfamily was affected by the Rab23 mutation. Since pSmad1/5/8 is the readout of global BMP signaling, another readout of the TGF signaling pathway, pSmad2/3, should be tested.

This is an excellent point. We now provide new additional information in figure (Figure 3---figure supplement 1C-D) that pSMAD2/3 along with pSMAD1/5/8 are not differentially expressed in Wt and RAB23 deficient sutures. This figure is now updated in revised manuscript.

> 8\) It is surprising that the epithelial, but not mesenchymal splice forms of FGFR1 are upregulated in suture and/or calvarial tissue. The authors should make some attempt to explain as to how or why this is the case if the sample should only contain mesenchymal cells.

We agree that it is surprising that the FGFR1b splice form, which is normally expressed in epithelia, is upregulated in the mesenchymal suture. However, this is not without precedent. While FGFRc isoforms are predominantly expresses in the mesenchyme and b isoforms in the epithelium, their expression is not mutually exclusive and FGFR1b is known to be expressed by late embryonic murine lung mesenchymal cells and also in the zebrafish in the sutural mesenchyme (Al Alam et al., 2015; Rice et al., 2003; Rice et al., 2004; Topczewska et al., 2016). Under pathological/force conditions mis-expression of splice forms can occur. Occasionally, Apert craniosynostosis syndrome is caused by heterozygous Alu-insertions or large deletions in the FGFR2c domalin. These rare mutations induce abnormal expression of the FGFR2b splice form alongside FGFR2c splice form in mesenchymal cells. This permits cells to respond to both b- and c-activating FGF ligands including FGF10 (Bochukova et al., 2009; Oldridge et al., 1999).

We have changed the manuscript text to elaborate on this surprising finding.
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